Cargando…

Metabolic dysfunction‐associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality

MAFLD often cooccurs with excessive alcohol consumption, while its prognostic value in this group remains unclear. We aimed to study the mortality risk of MAFLD in relation to excessive alcohol consumption and its potential interactions. APPROACH AND RESULTS: We analyzed persons 25–74 years old enro...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Kleef, Laurens A., de Knegt, Robert J., Brouwer, Willem Pieter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Original Articles: Steatohepatitis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936964/ https://www.ncbi.nlm.nih.gov/pubmed/35776631 http://dx.doi.org/10.1002/hep.32642

Ejemplares similares

Fatty liver disease is not associated with increased mortality in the elderly: A prospective cohort study
por: van Kleef, Laurens A., et al.
Publicado: (2023)

Macrophage‐derived MLKL in alcohol‐associated liver disease: Regulation of phagocytosis
por: Wu, Xiaoqin, et al.
Publicado: (2023)

The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent
por: Goikoetxea-Usandizaga, Naroa, et al.
Publicado: (2023)

The global fatty liver disease Sustainable Development Goal country score for 195 countries and territories
por: Lazarus, Jeffrey V., et al.
Publicado: (2023)

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
por: Younossi, Zobair M., et al.
Publicado: (2023)

Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease
por: Hall, Zoe, et al.
Publicado: (2017)

Metabolic dysfunction–associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study
por: van Kleef, Laurens A., et al.
Publicado: (2021)

IL-17 Signaling Accelerates the Progression of Nonalcoholic Fatty Liver Disease in Mice
por: Harley, Isaac TW, et al.
Publicado: (2014)

Intestinal peroxisome proliferator‐activated receptor α‐fatty acid‐binding protein 1 axis modulates nonalcoholic steatohepatitis
por: Yan, Tingting, et al.
Publicado: (2023)

Magnetic Resonance Elastography Predicts Advanced Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: A Prospective Study
por: Loomba, Rohit, et al.
Publicado: (2014)

Eliciting the mitochondrial unfolded protein response by nicotinamide adenine dinucleotide repletion reverses fatty liver disease in mice
por: Gariani, Karim, et al.
Publicado: (2015)

Fatty Liver Index and mortality after myocardial infarction: A prospective analysis in the Alpha Omega Cohort
por: Heerkens, Luc, et al.
Publicado: (2023)

Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B
por: van Kleef, Laurens A., et al.
Publicado: (2021)

Hypothalamic kappa opioid receptor mediates both diet‐induced and melanin concentrating hormone–induced liver damage through inflammation and endoplasmic reticulum stress
por: Imbernon, Monica, et al.
Publicado: (2016)

RIPK3 dampens mitochondrial bioenergetics and lipid droplet dynamics in metabolic liver disease
por: Afonso, Marta B., et al.
Publicado: (2023)

Metabolic profiling of fatty liver in young and middle‐aged adults: Cross‐sectional and prospective analyses of the Young Finns Study
por: Kaikkonen, Jari E., et al.
Publicado: (2016)

Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood
por: Decaris, Martin L., et al.
Publicado: (2016)

Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness
por: Indira Chandran, Vineesh, et al.
Publicado: (2023)

Myeloid p38 activation maintains macrophage–liver crosstalk and BAT thermogenesis through IL‐12–FGF21 axis
por: Crespo, María, et al.
Publicado: (2023)

Head-to-head comparison of magnetic resonance elastography-based liver stiffness, fat fraction, and T1 relaxation time in identifying at-risk NASH
por: Li, Jiahui, et al.
Publicado: (2023)

Vertical sleeve gastrectomy activates GPBAR‐1/TGR5 to sustain weight loss, improve fatty liver, and remit insulin resistance in mice
por: Ding, Lili, et al.
Publicado: (2016)

The Steatosis-associated fibrosis estimator (SAFE) score: validation in the general US population
por: van Kleef, Laurens A., et al.
Publicado: (2023)

Objectively Measured Physical Activity Is Inversely Associated With Nonalcoholic Fatty Liver Disease: The Rotterdam Study
por: van Kleef, Laurens A., et al.
Publicado: (2022)

Association of Nonalcoholic Fatty Liver Disease and Fibrosis With Incident Dementia and Cognition: The Rotterdam Study
por: Xiao, Tian, et al.
Publicado: (2022)

Relationship between NAFLD and coronary artery disease: A Mendelian randomization study
por: Ren, Zhewen, et al.
Publicado: (2023)

Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride‐rich lipoprotein metabolism
por: Deprince, Audrey, et al.
Publicado: (2023)

Lipocalin‐2 activates hepatic stellate cells and promotes nonalcoholic steatohepatitis in high‐fat diet–fed Ob/Ob mice
por: Kim, Kyung Eun, et al.
Publicado: (2023)

Enhanced mitochondrial activity reshapes a gut microbiota profile that delays NASH progression
por: Juárez‐Fernández, María, et al.
Publicado: (2023)

Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study
por: Anstee, Quentin M., et al.
Publicado: (2023)

Hepatic mitochondrial NAD(+) transporter SLC25A47 activates AMPKα mediating lipid metabolism and tumorigenesis
por: Cheng, Lili, et al.
Publicado: (2023)

Effect of Colesevelam on Liver Fat Quantified by Magnetic Resonance in Nonalcoholic Steatohepatitis: A Randomized Controlled Trial
por: Le, Thuy-Anh, et al.
Publicado: (2012)

Prospective evaluation of the diagnostic accuracy of hepatic copper content, as determined using the entire core of a liver biopsy sample
por: Yang, Xu, et al.
Publicado: (2015)

Reply to: “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”
por: van Kleef, Laurens A., et al.
Publicado: (2022)

A Phase 1/2, Dose-Escalation Trial of Deferasirox for the Treatment of Iron Overload in HFE-Related Hereditary Hemochromatosis
por: Phatak, Pradyumna, et al.
Publicado: (2010)

Apolipoprotein CIII Overexpressing Mice Are Predisposed to Diet-Induced Hepatic Steatosis and Hepatic Insulin Resistance
por: Lee, Hui-Young, et al.
Publicado: (2011)

Dissociation Between APOC3 Variants, Hepatic Triglyceride Content and Insulin Resistance
por: Kozlitina, Julia, et al.
Publicado: (2011)

Role of Patatin-Like Phospholipase Domain-Containing 3 on Lipid-Induced Hepatic Steatosis and Insulin Resistance in Rats
por: Kumashiro, Naoki, et al.
Publicado: (2013)

The small molecule, genistein, increases hepcidin expression in human hepatocytes
por: Zhen, Aileen W, et al.
Publicado: (2013)

Ezetimibe for the Treatment of Nonalcoholic Steatohepatitis: Assessment by Novel Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Randomized Trial (MOZART Trial)
por: Loomba, Rohit, et al.
Publicado: (2015)

Hypercaloric diets with increased meal frequency, but not meal size, increase intrahepatic triglycerides: A randomized controlled trial
por: Koopman, Karin E, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_m7e38b69apdfg815q9sf0d1587